NewsFeed Voices Science Insight Innovation
December, 2025
December 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
DOACs vs. Warfarin in Cerebral Venous Thrombosis: ACTION-CVT Study Shows Safer Profile Without Compromising Efficacy
Stroke AHA/ASA/X
Jun 12, 2025, 06:59

DOACs vs. Warfarin in Cerebral Venous Thrombosis: ACTION-CVT Study Shows Safer Profile Without Compromising Efficacy

Stroke AHA/ASA shared on X:

“STROKE In the Multicenter International Study ACTION CVT, patients with Cerebral Venous Thrombosis treated with DOACs had similar rate of thrombosis recurrence and recanalization rates, but lower risk of major hemorrhages, when compared to  warfarin (1/3)”

Title: Low incidence of thromboembolism with Fiix-monitored warfarin compared to conventional warfarin and DOACs in patients with AF.

Authors: Arnar B. Ingason, Brynja R. Gudmundsdottir, Ragnar Palsson, Johann P. Hreinsson, Sigrun H. Lund, Loic R. Letertre, Edward Rumba, Arnar S. Agustsson, Einar S. Bjornsson, Pall T. Onundarson.

DOACs vs. Warfarin in Cerebral Venous Thrombosis: ACTION-CVT Study Shows Safer Profile Without Compromising Efficacy

Read more about it in Blood Vessels, Thrombosis & Hemostasis (2025).

Discover more in Hemostasis Today.

 

Arnar B. Ingason Arnar S. Agustsson ASH Blood Vessels Brynja R. Gudmundsdottir BVTH 2025 Cerebral Venous Thrombosis DOACs DOACs vs. Warfarin Edward Rumba Einar S. Bjornsson Johann P. Hreinsson Loic R. Letertre Pall T. Onundarson. Ragnar Palsson Sigrun H. Lund Study ACTION CVT Thrombosis & Hemostasis Thrombosis and Haemostasis
NewsFeed